Impact of direct‐acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancers
Pharmacoepidemiology and Drug Safety2022Vol. 32(4), pp. 486–495
Citations Over TimeTop 12% of 2022 papers
Laurent Lam, Hélène Fontaine, Nathanaël Lapidus, Céline Dorival, Jonathan Bellet, Dominique Larrey, Pierre Nahon, Alpha Diallo, Carole Cagnot, Clovis Lusivika‐Nzinga, François Téoulé, Gilles Hejblum, Marc Bourlière, Stanislas Pol, Fabrice Carrat, for the ANRS/AFEF Hepather study group
Abstract
DAAs were not associated with extrahepatic cancer development or reduction. They were associated with a decreased risk of PAD and an increased risk of ACD, supporting long-term cardiac monitoring after DAA therapy.
Related Papers
- → Hepatology and Transplant Hepatology(2010)2 cited
- → Hepatology and Hepatology: the Good, the Bad, and the Ugly(1996)6 cited
- Evaluating the role of confounding in pharmacoeconomic studies.(2003)
- → HEPATOLOGY and hepatology: The good, the bad, and the ugly(1996)
- → P0320 AUTOIMMUNE HEPATITIS: MULTICENTRE DATA AT DIAGNOSIS IN 245 CHILDREN(2004)